版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、5/98;1The Coagulation Cascade Central to the coagulation cascade is the generation of thrombin (factor IIa) thrombin is generated from prothrombin by the action of activated factor X (Xa) thrombin then acts on fibrinogen to generate fibrin clot5/98;2Coagulation CascadeXIIaXIaIXaIntrinsic Pathway(sur
2、face contact)XaExtrinsic Pathway(tissue factor)VIIaThrombin (IIa)Thrombin-FibrinClotaPTTPTHeparin / LMWH(AT-III dependent)Hirudin/Hirulog(direct antithrombin)Courtesy of VTI 5/98;3THROMBOSISCollagen XIaTissue Factor IXaPlatelet ClumpingThrombus FormationThrombus GrowthHEMOSTASISTissue Factor &Co
3、llagenPlatelet AggregationPlatelet-richHemostatic PlugXaFluidThrombinHeparin Inhibits Hemostasis5/98;4The Procoagulant State in ThrombolysisAmplificationVascular InjuryActivation of PlateletsAnd CoagulationXa Thrombin (IIa)5/98;5Low-molecular-weight heparin UH (mw 3k - 30k) is a heterogeneous mixtur
4、e of polysacchride chains (glycosaminoglycans) LMWH (mw 5k) is obtained by alkaline degradation of heparin benzyl ester LMWH molecules are enriched with short chains with higher anti-Xa:IIa ratio5/98;6Mechanism of Action Both UH and LMWH exert their anticoagulation activity by catalyzing antithrombi
5、n (AT or AT III) catalyzed AT is accelerated in its inactivation of the coagulation enzymes thrombin (factor IIa) and factor Xa. prolongs aPTT5/98;7There are two heparin-cofactors, Antithrombin (AT) and Heparin Co-factor II (HC II).AT is an effective antithrombinbut HC II is a very weak antithrombin
6、ATHC II+- - - -Interaction of Heparin Co-Factors with ThrombinThrombinHFSCThrombinHFSC5/98;8ATHC II+- - - -Interaction of Heparin Co-Factors with ThrombinThrombinHFSCThrombinHFSCHeparin has a higher affinity for AT than for HC II and there is more AT in plasma than HC II5/98;9ATFree ThrombinAntithro
7、mbin and Free ThrombinAT alone does not inactivate free-thrombinThrombinHFSC5/98;10Heparin binds to antithrombin and increases the rate of thrombin inactivationATHeparinInactivation of Thrombin byHeparin-AT ComplexesThrombinHFSC5/98;11ATFibrin-Bound ThrombinThe rate at which AT inactivatesfibrin-bou
8、nd thrombin is reduced 50-foldEffect of Antithrombin on Fibrin-Bound ThrombinThrombinHFSC5/98;12Inactivation of Thrombin by Heparin-AT ComplexesWhen thrombin binds to fibrin, it becomes resistant to inactivation by heparin.ATHeparinFibrinThrombinHFSC5/98;13Mechanism of Action Summary Catalyzes ATIII
9、 Specific for fluid-phase thrombin Prolongs aPTT by inactivating thrombin and blocking Xa generation5/98;14Differences in Mechanism of Action Any size of heparin chain can inhibit the action of factor Xa by binding to antithrombin (AT) In contrast, in order to inactivate thrombin (IIa), the heparin
10、molecule must be long enough to bind both antithrombin and thrombin 2.0 mg/dl) obese patients with altered drug pK major bleeding risk factors aPTT not useful - low anti-IIa activity anti-factor Xa assay is more appropriate, but not widely available5/98;21ESSENCE TrialEfficacy and Safety of Subcutan
11、eousEnoxaparin in non-Q-Wave Coronary Events Study A randomized study comparing the clinical efficacy of UFH vs enoxaparin LMWH in 3171 patients with rest angina or non-Q-wave MI at 30 days, there was a relative risk reduction of 15% -16% in the rate of death, MI, or refractory ischemia as compared
12、to standard heparinN Eng J Med 1997;337:447-4525/98;2230 days Enox HepIncidence of death, MI, angina14 d 16.6% 19.8% p=.01930 d 19.8% 23.3% p=.016Minor bleeding30 d 13.8% 8.8% p.001Major bleeding30 d 6.5% 7.0% NSDeath alone14 d 2.2% 2.3% NS30 d 2.9% 3.6% NS5/98;2343 days5/98;24TIMI 11BLMWH in Unstab
13、le Angina 4,021 pts with acute coronary syndrome Two treatment groups:UFH: 70 U/kg bolus 15 u/kg/hr iv LMWH: 30 mg bolus 1 mg/kg s.q. bid Primary endpoint(death, MI, urgent revascularization)48-72 hr26%14 days15%p0.03Circulation 1999; 100:1593-16015/98;25Meta-AnalysisESSENCE and TIMI 11BPrimary endp
14、oint Death / MI / Urgent RevscularizationOdds ratioRisk Reductionp-valDay 8 0.7121%0.02Day 14 0.7921%0.0005Day 43 0.8020%0.0006European Society of Cardiology - August 19985/98;26Primary Endpoint : Day 43Death/MI/Urgent Revasc002244668810101212141416161818202000448812121616202024242828323236364040444
15、4P=0.048RRR 12 %P=0.048P=0.048RRR 12 %RRR 12 %UFHUFHUFHENOXENOXENOX19.7 %19.7 %19.7 %17.3 %17.3 %17.3 %DaysDaysDays5/98;27Difference Between Lovenox and Heparin LovenoxHeparinHalf-life (hr) 4.5 dose-dependentAnti-Xa:IIa 14:1 1:1Molecular wt (avg) 4,500 15,000Time to peak activity 3-5 2-4Dosing units
16、 mg IU4/00;28Enoxaparin in DVT ProphylaxisDOSAGEDURATIONin patients undergoing 30 mg q12h SCaverage duration: 7 to 10 dayship-replacement surgeryinitiate 12-24h postopup to 14 days40 mg qd SCinitiated 12h (3) preopextended prophylaxis in40 mg qd SC3 weeks post dischargehip replacementin patients und
17、ergoing 30 mg q12h SCaverage duration: 7 to 10 daysknee-replacement surg initiate 12-24h postopin patients undergoing 40 mg qd SCaverage duration: 7 to 10 daysabdominal surgeryinitiate 2h preop4/00;29Enoxaparin in Treatment ofin acute DVT with or without PEDOSAGEDURATIONFor patients who can be1 mg q
18、12h SCcontinue LOVENOX for a treated at home for acute initiate warfarin sodiumminimal of 5 days and untilDVT without PEtherapy when appropriate a therapeutic oral anticoagulant (usually within 72h ofeffect has been achieved (INRLovenox administration)2.0 to 3.0).average duration: 7 days For hospita
19、lized patients 1.5 mg/kg qd SC at the with acute DVT with or same time every day orwithout PE1 mg/kg q12h SC4/00;30Enoxaparin for UA and non-Q MIDOSAGEDURATIONFor the prevention of1 mg/kg q12h SCminimum 2 days; usual duration ischemic complications with oral aspirin therapyof therapy: 2 to 8 daysof
20、unstable angina and (100 to 325 mg once daily)non-Q-wave myocardialinfarction (MI) whenconcurrently administeredwith aspirin5/98;31Economic Assessment of LMWH vs UFHResults from the ESSENCE Trail enoxaparin heparinNeed for coronary angioplasty (initial)15%20% p=.04 coronary angioplasty (30d)18%22% p=.08 diagnostic cath (30d)57%63% p=.04 Initial hospitalization mean drug cost in U.S.*$155$80 mean total cost of care$11,857$12,620mean du
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2024-2030年便携式金属探测器行业市场现状供需分析及重点企业投资评估规划分析研究报告
- 2024-2030年住宅太阳能储能系统行业市场现状供需分析及重点企业投资评估规划分析研究报告
- 2024-2030年伽玛刀行业投资机会及风险投资运作模式研究报告
- 2024-2030年休闲健身器材行业市场深度调研及前景趋势与投资研究报告
- 2024-2030年人造石英石(EQS)行业市场现状供需分析及重点企业投资评估规划分析研究报告
- 2024-2030年交通安全产品行业市场现状供需分析及重点企业投资评估规划分析研究报告
- 2024-2030年乙醇项目可行性研究报告
- 2024-2030年丹参行业市场发展现状及发展前景与投资机会研究报告
- 2024-2030年中国鼠标行业竞争态势及销售趋势预测报告
- 2024-2030年中国黄酒行业竞争策略与销售动态预测报告
- 2024年安全生产月专题培训课件
- 2024届东北三省高三下学期5月份大联考物理试卷
- 教育学课件完整版
- 武术套路智慧树知到期末考试答案章节答案2024年沈阳体育学院
- 消费者行为分析智慧树知到期末考试答案章节答案2024年北京财贸职业学院
- 《人类起源的演化过程》阅读测试题及答案
- 宜昌华美达酒店开业活动策划提案
- 除氧器水位自动调节原理.doc
- 西南大学《中兽医学》网上作业及参考答案.doc
- 【中考12年】北京市2002中考数学试题分类解析 专题12 押轴题.doc
- 华为公司伙伴关系管理PRM系列宣传(第1-20期)
评论
0/150
提交评论